Impact of Eli Lilly v. Teva Parenteral Medicines Inc. on Divided Infringement

Quinn Emanuel Urquhart & Sullivan, LLP
Contact

Quinn Emanuel Urquhart & Sullivan, LLP

The Federal Circuit in Eli Lilly v. Teva Parenteral Medicines Inc., 845 F.3d 1357 (Fed. Cir. 2017), recently addressed the issue of “divided infringement” in the context of pharmaceutical patents for the first time since its 2015 decision in Akamai Technologies Inc. v. Limelight Networks, Inc., 797 F.3d 1020 (Fed. Cir. 2015) (“Akamai V”). Divided infringement occurs when multiple actors are involved in carrying out the claimed infringement of a method patent and no single accused infringer has performed all of the steps of the method. In cases of divided infringement, courts will generally hold a defendant infringer liable for the infringing actions of another where the defendant directs or controls the other’s actions or forms a joint enterprise or acts with a common purpose together with the other. See Akamai V, 797 F.3d at 1022.

In Eli Lilly, the Federal Circuit reviewed the question of what constitutes directing another’s actions in cases where pharmaceutical drug labeling information provides firm directions to physicians to instruct the patient to self-perform certain steps of a patented treatment method. The Court held that where the drug labeling information provides the required steps that physicians must direct patients to take prior to administering the drug, and provides firm instructions to the physicians relative to the drug’s administration, the drug manufacturer can be held liable for inducing infringement of a method-of-use patent.

Case Background
Pharmaceutical company Eli Lilly, the plaintiff in this case, holds a patent relating to the treatment of cancer, and specifically relating to methods for administering the drug pemetrexed disodium (“pemetrexed”). Pemetrexed is a chemotherapy drug that kills cancer cells that Eli Lilly sells under the brand name ALIMTA®. Treatment with permetrexed requires physicians first to treat the patient with folic acid and vitamin B12 before administering the drug, which reduces the drug’s toxicity and increases safety. The pemetrexed patent states that the process of drug treatment requires “administering an effective amount of folic acid” to the patient, specifically “between about 350 µg and about 1000 µg.”

The defendants were a collection of generic drug companies that sought to sell generic versions of ALIMTA® prior to the expiration of Eli Lilly’s patent. The defendants planned to sell pemetrexed for the same purpose as the patented method—to use pemetrexed to treat cancer cells after first reducing the toxicity using folic acid and vitamin B12. They nevertheless argued that they did not infringe Eli Lilly’s patent because the steps that defendants proposed would be taken would be divided between physicians and patients, where the patient self-administers folic acid with guidance from the physician, while the physician administers vitamin B12 and pemetrexed.

To show that these two actions amounted to divided infringement, Eli Lilly had to show that the defendants induced direct infringement of the patent from multiple parties by establishing that “the acts of one are attributable to the other such that a single entity is responsible for the infringement.” This occurs in two types of circumstances: when the entity “directs or controls” another’s performance, or when the actors “form a joint enterprise.” See Akamai V, 797 F.3d at 1022. The question in Eli Lilly was whether the defendants infringed Eli Lilly’s patent because it called for the physician to “direct or control” the patient’s performance. Following a bench trial, the district court determined that it did, and the Federal Circuit affirmed that decision.

Directing or Controlling Performance
Relying upon prior Federal Circuit precedent, in particular Akamai V, the court noted that “directing or controlling others’ performance includes circumstances in which an actor: (1) ‘conditions participation in an activity or receipt of a benefit’ upon others’ performance of one or more steps of a patented method, and (2) ‘establishes the manner or timing of that performance.’” Eli Lilly, 845 F.3d at 1365. Given that the permetrexed labeling information, including the physician prescribing information and the patient instructions, established clear directions and methods of compliance that physicians were required to give to patients prior to administering the drug, the court concluded that defendants were liable for divided infringement by “directing and controlling” the other infringers’ actions. With respect to the first prong, the district court “identified pemetrexed treatment as the benefit to be conditioned.” The product labeling repeatedly tells physicians to instruct patients on taking folic acid, along with folic acid dosage ranges and schedules. Likewise, the patient information informs patients that the physician may withhold pemetrexed treatment, with both sides’ experts acknowledging that if the physician knew that the patient did not first take the required amount of folic acid, any reputable physician would withhold treatment of pemetrexed. Thus, the Federal Circuit agreed that physicians do not merely “guide or instruct” the patients to take folic acid, but rather condition participation in administering pemetrexed upon the patient first taking folic acid.

With respect to the second prong, Defendants argued that because the product labeling gives patients wide latitude to select the dose, the form of dose, and the timing of taking the folic acid, it cannot be said that the physician “establishes the manner or timing of [] performance.” In rejecting these arguments, the Federal Circuit again focused on the product labeling, noting that the physician prescribing information instructs physicians to tell patients to take folic acid orally and to take between 400 µg and 1000 µg of folic acid daily for one week before the start of pemetrexed. These instructions overlap with the dosage ranges and schedules in Eli Lilly’s patent, and thus the Federal Circuit determined that Eli Lilly satisfied the second prong.

Intent to Induce Infringement
Having found the two-prong Akamai V test met, the court next turned to the question of whether Eli Lilly proved that defendants had “specific intent and action to induce infringement.” The district court found that defendants had acted with such specific intent, because the administration of folic acid was a critical step for the administration of pemetrexed—not just a suggestion or recommendation—and because the defendants’ proposed labeling induced the physicians to act in accordance with that labeling. In upholding that decision, the Federal Circuit noted that the intent must be directed to the actions of the underlying direct infringer, here the physicians, but it is not necessary for the plaintiff to provide evidence regarding whether the induced activity is actually prevalent. Rather, when proving intent based upon product labeling, the “label must encourage, recommend, or promote infringement” in order for the court to be able to infer an affirmative intent to infringe the patent. If the instructions clearly instruct users to follow the instructions in an infringing manner, then the court will find intent to induce infringement, even if some users might not follow the instructions. On the other hand, if the instructions are vague and require the actor to look outside the label to understand and undertake the implied infringing action, then an intent to induce infringement cannot necessarily be inferred. In this case, the product labeling made clear what was required of the physician, including the instructions to convey to the patient. Although defendants argued that physicians often take additional steps not considered by the patent, such as asking patients to keep pill diaries or confirming compliance with folic acid administration, the court determined that these additional guidelines are irrelevant to the question of inducement whenever the product labeling would inevitably lead some physicians to infringe the patent.

Divided Infringement Going Forward
In light of the Federal Circuit decision in Eli Lilly, in order for a patent holder to succeed on a claim of divided infringement against a company seeking to market a generic drug by incorporating steps to be taken by different actors, the patent holder must show that the generic drug company intentionally induced a party, such as a physician, to infringe the patent by either directing or controlling the other party to engage in actions that—together with the actions of the controlling party—would infringe the patent, or by joining into an enterprise with the other party and jointly infringing the patent. Where Eli Lilly is additive to the existing body of case law on this question is that it identifies the drug labeling information used by the generic company as particularly important evidence both in establishing direction or control and in establishing an intent to induce infringement. If the generic company includes in its labeling to the United State Food and Drug Administration that certain tests or steps must be performed by the physician or under the physician’s direction, then according to Eli Lilly, infringement will likely be found. If, on the other hand, the generic company is able to avoid definite requirements in the product labeling, instead leaving it to the physician to independently determine the method of administration, Eli Lilly suggests that it may be more difficult for the patent holder to establish the requirements to hold the generic company liable for divided infringement. Eli Lilly expressly did not reach the question whether more than just a patient-physician relationship is required to show that the patient is acting under the physician’s “direction or control,” while also leaving open the possibility that other scenarios not involving directions to physicians in FDA-approved labels could serve to satisfy the “direction or control” requirement.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Quinn Emanuel Urquhart & Sullivan, LLP | Attorney Advertising

Written by:

Quinn Emanuel Urquhart & Sullivan, LLP
Contact
more
less

Quinn Emanuel Urquhart & Sullivan, LLP on:

Readers' Choice 2017
Reporters on Deadline

Related Case Law

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.